Meeting
2021 ASCO Annual Meeting
A phase I dose-escalation and expansion study of JPI-547, a dual inhibitor of PARP/tankyrase in patients with advanced solid tumors.
Authors
Seock-Ah Im
Seoul National University Hospital, Seoul, South Korea
Seock-Ah Im , SeungHwan Lee , Keun Wook Lee , Youngjoo Lee , Joohyuk Sohn , Jee Hyun Kim , Young-Hyuck Im , Kyong Hwa Park , Do-Youn Oh , Min Hwan Kim , Yeon Hee Park , Tae Min Kim , Yoon Ji Choi , Chang-Seok Lee , Jiseon Park , Nam Seok Baek , MiKyung CHOI , John Kim , Eunyoung Yu , Yung-Jue Bang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT04335604
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 3113)
DOI
10.1200/JCO.2021.39.15_suppl.3113
Abstract #
3113
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Safety and preliminary efficacy of MIL93 in patients with advanced solid tumors: The monotherapy part of a phase 1 trial.
First Author: Jing Huang
Poster
2021 ASCO Annual Meeting
A phase I study of an IDO inhibitor (SHR9146) plus camrelizumab and in combination with/without apatinib in patients with advanced solid tumors: Safety and efficacy analysis.
First Author: Ying Cheng
Poster
2021 ASCO Annual Meeting
Phase 1b/2 SEASTAR trial: Safety, pharmacokinetics, and preliminary efficacy of the poly(ADP)-ribose polymerase (PARP) inhibitor rucaparib and angiogenesis inhibitor lucitanib in patients with advanced solid tumors.
First Author: Ecaterina Elena Dumbrava
Poster
2020 Gastrointestinal Cancers Symposium
Safety, pharmacokinetics, and efficacy of RC48-ADC in a phase I study in patients with HER2-overexpression advanced solid cancer.
First Author: Jifang Gong